Repotrectinib
- Generic Name
- Repotrectinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18FN5O2
- CAS Number
- 1802220-02-5
- Unique Ingredient Identifier
- 08O3FQ4UNP
- Indication
用于ROS1阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 30
- Registration Number
- NCT06552234
- Locations
- 🇫🇷
CH Aix-en-Provence, Aix-en-Provence, Bouches Du Rhône, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷Centre François Baclesse, Caen, France
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06493409
- Locations
- 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT06408168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT06352528
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Local Institution - 0005, Orlando, Florida, United States
🇺🇸Local Institution - 0006, Miami Lakes, Florida, United States
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
- Conditions
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 20
- Registration Number
- NCT06315010
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT06140836
- Locations
- 🇮🇳
Grant Medical Foundation - Ruby Hall Clinic, Pune, Maharashtra, India
🇺🇸Local Institution - 0136, Augusta, Georgia, United States
🇺🇸Local Institution - 0221, Des Moines, Iowa, United States
Expanded Access for Repotrectinib
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05926232
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05828303
- Locations
- 🇪🇸
Local Institution - 2138, Madrid, M, Spain
🇺🇸Local Institution - 2102, Denver, Colorado, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05071183
- Locations
- 🇺🇸
Local Institution - 2107, Houston, Texas, United States
🇺🇸Local Institution - 2102, Virginia Beach, Virginia, United States
🇺🇸Local Institution - 2101, California City, California, United States
A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05004116
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.